We are live on ! Find out more

Biogen

BIIB

Market cap $36.8B

249.01 USD

-4.61

1.82%

At close Updated Nov 2, 4:00 PM EST

Pre-market

After hours

249.01

0.00

0%

1 day

-1.82%

5 days

-0.54%

1 month

13.25%

3 months

23.38%

6 months

33.01%

Year to date

40.03%

1 year

64.43%

5 years

-8.62%

10 years

-10.19%

About: Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Employees: 7,500

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 47.7%

Neutral 50%

Negative 2.3%

These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter.

These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab presentations will highlight new long-term and real-world evidence, including initial five-year Clarity AD open-label extension data and three-year LEADER data, with new analyses exploring maintenance treatment and at-home subcutaneous administration Presentations across Biogen's Alzheimer's disease portfolio reflect its continued commitment to advancing innovation in Alzheimer's disease, from long-term treatment outcomes and real-world evidence to investigational approaches targeting core disease pathologies, including amyloid and tau CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place November 16–19, 2026, at the Boston Marriott Copley Place in Boston, Massachusetts.

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

Biogen Q3 Earnings Call Highlights

Biogen NASDAQ: BIIB reported third-quarter 2026 revenue growth of 11% year over year, supported by its acquisition of Apellis and continued expansion of its growth-product portfolio. Management said the company remains on track to return to top-line growth in 2026 and raised the lower end of its full-year non-GAAP diluted earnings-per-share guidance.

Biogen Q3 Earnings Call Highlights

Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript

Biogen Inc. ( BIIB ) Q3 2026 Earnings Call October 28, 2026 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - Executive VP & Head of Development Robin Kramer - Executive VP & CFO Alisha Alaimo - President & Head of North America Conference Call Participants Philip Nadeau - TD Cowen, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Michael Yee - UBS Investment Bank, Research Division Alexandria Hammond - Wolfe Research, LLC Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Evan Seigerman - BMO Capital Markets Equity Research Geoffrey Meacham - Citigroup Inc., Research Division David Amsellem - Piper Sandler & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Lin Tsai - Jefferies LLC, Research Division Marc Goodman - Leerink Partners LLC, Research Division Presentation Operator Good morning. My name is Cynthia, and I will be your conference operator today.

Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript

Zacks Investment Research

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Zacks Investment Research

Big Day for Econ Data, Hyperscaler Earnings

We have a solid slate of reports today, both of the earnings variety and regarding economic growth.

Big Day for Econ Data, Hyperscaler Earnings

Zacks Investment Research

Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

Biogen Inc. (BIIB) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $4.81 per share a year ago.

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

Biogen Swings to Loss, Logs Higher Sales

The biotechnology company said the swing to a loss was primarily due to transaction-related charges.

Biogen Swings to Loss, Logs Higher Sales

Investors Business Daily

Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report

Biogen crushed third-quarter expectations early Tuesday, helped by its suite of newer products and leading to a guidance boost.

Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report

See News Rankings

Price charts implemented using Lightweight Charts™